MRI-based radiomics analysis for predicting the EGFR mutation based on thoracic spinal metastases in lung adenocarcinoma patients

被引:26
|
作者
Ren, Meihong [1 ]
Yang, Huazhe [2 ]
Lai, Qingyuan [3 ]
Shi, Dabao [3 ]
Liu, Guanyu [3 ]
Shuang, Xue [1 ]
Su, Juan [1 ]
Xie, Liping [4 ]
Dong, Yue [3 ]
Jiang, Xiran [1 ]
机构
[1] China Med Univ, Sch Fundamental Sci, Dept Biomed Engn, Shenyang 110122, Peoples R China
[2] China Med Univ, Sch Fundamental Sci, Dept Biophys, Shenyang, Peoples R China
[3] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Radiol, Shenyang 110042, Peoples R China
[4] Northeastern Univ, Coll Med & Biol Informat Engn, Shenyang, Peoples R China
基金
中国国家自然科学基金;
关键词
EGFR; MRI; thoracic spinal metastases; FACTOR RECEPTOR MUTATION; BONE METASTASES; CANCER; CLASSIFICATION; FEATURES;
D O I
10.1002/mp.15137
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: This study aims to develop and evaluate multi-parametric MRI-based radiomics for preoperative identification of epidermal growth factor receptor (EGFR) mutation, which is important in treatment planning for patients with thoracic spinal metastases from primary lung adenocarcinoma. Methods: A total of 110 patients were enrolled between January 2016 and March 2019 as a primary cohort. A time-independent validation cohort was conducted containing 52 patients consecutively enrolled from July 2019 to April 2021. The patients were pathologically diagnosed with thoracic spinal metastases from primary lung adenocarcinoma; all underwent T1-weighted (T1W), T2- -weighted (T2W), and T2-weighted fat-suppressed (T2FS) MRI scans of the thoracic spinal. Handcrafted and deep learning-based features were extracted and selected from each MRI modality, and used to build the radiomics signature. Various machine learning classifiers were developed and compared. A clinical-radiomics nomogram integrating the combined rad signature and the most important clinical factor was constructed with receiver operating characteristic (ROC), calibration, and decision curves analysis (DCA) to evaluate the prediction performance. Results: The combined radiomics signature derived from the joint of three modalities can effectively classify EGFR mutation and EGFR wild-type patients, with an area under the ROC curve (AUC) of 0.886 (95% confidence interval [CI]: 0.826-0.947, SEN =0.935, SPE =0.688) in the training group and 0.803 (95% CI: 0.682- -0.924, SEN = 0.700, SPE = 0.818) in the time-independent validation group. The nomogram incorporating the combined radiomics signature and smoking status achieved the best prediction performance in the training (AUC = 0.888, 95% CI: 0.849-0.958, SEN = 0.839, SPE = 0.792) and time-independent validation (AUC = 0.821, 95% CI: 0.692-0.929, SEN = 0.667, SPE = 0.909) cohorts. The DCA confirmed potential clinical usefulness of our nomogram. Conclusion: Our study demonstrated the potential of multi-parametric MRI-based radiomics on preoperatively predicting the EGFR mutation. The proposed nomogram model can be considered as a new biomarker to guide the selection of individual treatment strategies for patients with thoracic spinal metastases from primary lung adenocarcinoma.
引用
下载
收藏
页码:5142 / 5151
页数:10
相关论文
共 50 条
  • [31] Spectral CT based radiomics for predicting brain metastases in patients with lung cancer
    Cao, S.
    Shu, Z.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2024, 22 (02):
  • [32] MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma
    Wang, Yuxin
    Liu, Zhenhao
    Xu, Hui
    Yang, Dawei
    Jiang, Jiahui
    Asayo, Himeko
    Yang, Zhenghan
    BMC MEDICAL IMAGING, 2023, 23 (01)
  • [33] MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma
    Yuxin Wang
    Zhenhao Liu
    Hui Xu
    Dawei Yang
    Jiahui Jiang
    Himeko Asayo
    Zhenghan Yang
    BMC Medical Imaging, 23
  • [34] MRI-Based Radiomics Models for Predicting Risk Classification of Gastrointestinal Stromal Tumors
    Mao, Haijia
    Zhang, Bingqian
    Zou, Mingyue
    Huang, Yanan
    Yang, Liming
    Wang, Cheng
    Pang, PeiPei
    Zhao, Zhenhua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] MRI-based bone marrow radiomics for predicting cytogenetic abnormalities in multiple myeloma
    Xiong, X.
    Wang, J.
    Hao, Z.
    Fan, X.
    Jiang, N.
    Qian, X.
    Hong, R.
    Dai, Y.
    Hu, C.
    CLINICAL RADIOLOGY, 2024, 79 (04) : e491 - e499
  • [36] Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma
    Shen, Hesong
    Wang, Yu
    Liu, Daihong
    Lv, Rongfei
    Huang, Yuanying
    Peng, Chao
    Jiang, Shixi
    Wang, Ying
    He, Yongpeng
    Lan, Xiaosong
    Huang, Hong
    Sun, Jianqing
    Zhang, Jiuquan
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [37] Multiparametric MRI-based Radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer
    Cheng, Yuan
    Luo, Yahong
    Hu, Yue
    Zhang, Zhaohe
    Wang, Xingling
    Yu, Qing
    Liu, Guanyu
    Cui, Enuo
    Yu, Tao
    Jiang, Xiran
    ABDOMINAL RADIOLOGY, 2021, 46 (11) : 5072 - 5085
  • [38] A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
    Zhou, S.
    Li, Y.
    Xu, W.
    Fei, Y.
    Wu, M.
    Yuan, J.
    Qiu, L.
    Cao, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S398 - S398
  • [39] Multiparametric MRI-based Radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer
    Yuan Cheng
    Yahong Luo
    Yue Hu
    Zhaohe Zhang
    Xingling Wang
    Qing Yu
    Guanyu Liu
    Enuo Cui
    Tao Yu
    Xiran Jiang
    Abdominal Radiology, 2021, 46 : 5072 - 5085
  • [40] MRI-based multiregional radiomics for predicting lymph nodes status and prognosis in patients with resectable rectal cancer
    Li, Hang
    Chen, Xiao-li
    Liu, Huan
    Lu, Tao
    Li, Zhen-lin
    FRONTIERS IN ONCOLOGY, 2023, 12